Arteriosclerosis and coronary artery disease - Strength and weakness in the classic risk factor concept;Arteriosklerose und koronare herzerkrankung - Starken und lucken im klassischen risikofaktorenkonzept

Herz

Volumn 23, Issue 3, 1998, Pages 153-162

  Schaefer, Jürgen R ^a   Herzum, Matthias ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Coronary artery disease; Hypercholesterolemia; Risk factor

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTERIOSCLEROSIS; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION; RISK FACTOR; SECONDARY PREVENTION; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; MALE; REVIEW;

CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; RISK FACTORS;

EID: 0031970957     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044600     Document Type: Article

References (12)

1. Assmann G, Schulte H. PROCAM-Studie. Hedingen-Zürich: Panscientia Verlag, 1986.
2. Cremer P, Elster H, Labrot B, el al. Incidence rates of fatal and nonfatal myocardial infarction in relation to the lipoprotein profile. Klin Wochenschr 1988;66:42.
3. Epstein FH. Risikofaktor, Risikoindikator und Pathogenese. Med Klin 1978;73:381.
4. Gefeller O, Muche R, Nagel D, et al. Cholesterinscreening: Vergleich verschiedener Strategien anhand der Daten der GRIPS-Studie. In: Kochen MM, Hrsg. Rationale Pharmakotherapie in der Allgemeinpraxis. Berlin-Heidelberg-New York: Springer, 1991:95.
5. Grundy SM, Balady GJ, Criqui MH, et al. AHA Science Advisories. Guide to primary prevention of cardiovascular diseases: A statement for healthcare professionals from the task force on risk reduction. Circulation 1997;95:2329.
6. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med 1992;326:1406:
7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383.
9. Schäfer JR. Präventive Kardiologie. Prophylaxe der koronaren Herzkrankheit. Stuttgart-New York: Schattauer, 1998.
10. Schmidt JG. Cholesterinscreening: Die Irrationalität von Grenzwerten und die Berücksichtigung des Gesamtrisikos für eine rationale Therapic. In: Kochen MM, Hrsg. Rationale Pharmakotherapie in der Allgemeinpraxis. Berlin-Heidelberg-New York: Springer, 1991:67.
11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravasiatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301.
12. Stamler J. Life styles, major risk factors, proof and public policy. Circulation 1978;58:3.